Advertisement

Topics

Serono Japan Company Limited Company Profile

19:21 EST 22nd November 2017 | BioPortfolio

We are one of the world’s top three biotechnology companies, with revenues of USD 1.38 billion (2001).

We currently focus on three core therapeutics areas:



Reproductive Health Multiple Sclerosis

Growth & Metabolism



We are also investing strongly in the future, as expressed by our New Therapeutic Areas.



Global reach

We operate in 45 countries and have sales in over 100 countries.

Location

Kokusai Sanno Building 9th Fl.
3-3-5 Akasaka, Minato-ku
Tokyo
107-0052
Japan

Contact

Phone: +81-3-5545-7200
Fax: +81-3-5545-7209


News Articles [427 Associated News Articles listed on BioPortfolio]

Merck Serono: Launching a New Corporate Venture Fund

In this episode of PharmaTelevision News Review, Paul Larsmon talks with Roel Bulthuis, Head at Merck Serono Ventures. Filmed at BIO-Europe 2009, they discuss: • Merck Serono's new corporate venture...

Roel Bulthuis of Merck Serono Ventures- looking for new investment opportunities in oncology, neurodegeneration, inflammation, fertility and endocrinology

In this episode of PharmaTelevision News Review, Fintan Walton talks to Roel Bulthuis, Head of Merck Serono Ventures of Merck Serono SA

Merck Serono Secures Future Pipeline

In March 2009 Merck Serono announced that they had set up a strategic Venture Fund to invest in biotech companies with interesting programmes that are in line with Merck Serono’s strategic thinking....

FDA designates orphan status to EMD Serono's gastric cancer drug

Merck KGaA unit EMD Serono's Bavencio, or avelumab, was given orphan drug designation by the FDA to treat patients with gastr -More- 

Phillippe Lopes-Fernandes talks about Merck Serono’s strengths and successes in partnering

In this episode of PharmaTelevision News Review, Fintan Walton talks to Phillippe Lopes-Fernandes, Corporate VP, Head of Global Business Development at Merck Serono

EMD Serono: Philippe M Lopes-Fernandes. Closure of Geneva site creates opportunities for new business successes

In this episode of PharmaTelevision News Review, filmed at BioEurope Spring 2013, in Barcelona, Spain, Fintan Walton talks to Philippe M Lopes-Fernandes, Senior VP, Head of Global Licensing, Business ...

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...

Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, ser...

PubMed Articles [472 Associated PubMed Articles listed on BioPortfolio]

Avelumab: First Global Approval.

Avelumab (Bavencio(®)) is an intravenously administered programmed cell death ligand-1-blocking human antibody initially developed by EMD Serono Inc. (the biopharmaceutical division of Merck KGaA, Da...

Cumulative incidence of Kawasaki disease in Japan.

Although the nationwide surveys of Kawasaki disease (KD) in Japan have revealed the incidence rates of KD in this country, cumulative incidences, e.g., the proportion of those with a history of KD amo...

First progress report on the Japan Endoscopy Database (JED) project.

The Japan Endoscopy Database (JED) Project was initiated to develop the world's largest endoscopic database, capture the actual performance of endoscopic practice, and standardize the terminology and ...

Trend and treatment status of latent tuberculosis infection patients in Japan - Analysis of Japan TB Surveillance data.

Management of latent tuberculosis infection (LTBI) is one of the core elements of End TB Strategy. Japan is one of the few countries in which notification of LTBI is mandatory, yet so far, the data ha...

Japan Prize/Special Award in Synthetic Organic Chemistry, Japan/CNRS Medals.

Clinical Trials [398 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Human FSH Versus Recombinant FSH (Follitropin Alpha) in ICSI.

Purpose of the study is the comparative evaluation of the clinical efficacy and of the general tolerability of two different subcutaneous FSH preparations (Fostimon® IBSA Vs Gonal-F® Ser...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Study of EMD531444 in Subjects With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Darmstadt, Germany, June 17 2010 - Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome ...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germa...

Companies [1885 Associated Companies listed on BioPortfolio]

Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono ...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Serono Japan Company Limited

We are one of the world’s top three biotechnology companies, with revenues of USD 1.38 billion (2001).We currently focus on three core therapeutics areas:Reproductive Health Multiple Sclerosis Growt...

Serono Inc.

Serono is a global biotechnology leader with over 4,750 employees and worldwide revenues of USD 2,586.4 million in the year 2005. We have eight biotechnology products on the market and currently more ...

Serono Laboratories Incorporated

We develop innovative products to fight debilitating diseases and improve the lives of our patients.We aspire to create an environment that enables our people to excel and innovate and to contribute t...

More Information about "Serono Japan Company Limited" on BioPortfolio

We have published hundreds of Serono Japan Company Limited news stories on BioPortfolio along with dozens of Serono Japan Company Limited Clinical Trials and PubMed Articles about Serono Japan Company Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Serono Japan Company Limited Companies in our database. You can also find out about relevant Serono Japan Company Limited Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...


Corporate Database Quicklinks



Searches Linking to this Company Record